NO20092145L - Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon - Google Patents

Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon

Info

Publication number
NO20092145L
NO20092145L NO20092145A NO20092145A NO20092145L NO 20092145 L NO20092145 L NO 20092145L NO 20092145 A NO20092145 A NO 20092145A NO 20092145 A NO20092145 A NO 20092145A NO 20092145 L NO20092145 L NO 20092145L
Authority
NO
Norway
Prior art keywords
combination
sexual dysfunction
androstiol
alfa
optionally
Prior art date
Application number
NO20092145A
Other languages
English (en)
Norwegian (no)
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes De Lange
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of NO20092145L publication Critical patent/NO20092145L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20092145A 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon NO20092145L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PCT/NL2007/050534 WO2008054214A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
NO20092145L true NO20092145L (no) 2009-07-21

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20092145A NO20092145L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon
NO20092146A NO20092146L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
NO20092143A NO343597B1 (no) 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20092146A NO20092146L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
NO20092143A NO343597B1 (no) 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon

Country Status (27)

Country Link
US (10) US8575139B2 (enExample)
EP (5) EP1925307A1 (enExample)
JP (8) JP2010509211A (enExample)
KR (6) KR20090115113A (enExample)
CN (6) CN101557812A (enExample)
AU (3) AU2007314735B2 (enExample)
BR (3) BRPI0717963A2 (enExample)
CA (3) CA2668317C (enExample)
CY (1) CY1117191T1 (enExample)
DK (1) DK2086544T3 (enExample)
ES (1) ES2561946T3 (enExample)
HR (1) HRP20160108T1 (enExample)
HU (1) HUE026752T2 (enExample)
IL (5) IL198459A (enExample)
ME (1) ME02410B (enExample)
MX (3) MX2009004696A (enExample)
NO (3) NO20092145L (enExample)
NZ (3) NZ577393A (enExample)
PH (2) PH12014501440A1 (enExample)
PL (1) PL2086544T3 (enExample)
PT (1) PT2086544E (enExample)
RS (1) RS54541B1 (enExample)
RU (4) RU2464027C2 (enExample)
SI (1) SI2086544T1 (enExample)
UA (4) UA100119C2 (enExample)
WO (3) WO2008054214A2 (enExample)
ZA (3) ZA200903837B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52945B (sr) 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
CN103648487B (zh) * 2011-05-13 2019-04-19 Eb Ip希博里塔布斯有限责任公司 药物递送系统
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
EP3108987A4 (en) 2014-02-21 2018-02-07 Kochi University, National University Corporation Method for producing nickel powder
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69420746T2 (de) 1994-06-02 2000-06-29 Dan Riga Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
TR199700930T2 (xx) 1995-03-14 1998-07-21 Vivus Incorporated Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1996036339A2 (en) * 1995-05-15 1996-11-21 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
AU756136B2 (en) * 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CA2377339A1 (en) 1999-06-17 2000-12-28 Armin Johannes Becker Administration of growth hormone (hgh) for the therapy of sexual functional disorders
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
JP2004524267A (ja) 2000-08-30 2004-08-12 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 男性の勃起障害の治療方法、及び性衝動の増強方法
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
CA2426666A1 (en) 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
AU2002220977A1 (en) * 2000-12-15 2002-06-24 Pfizer Inc. Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
KR100564466B1 (ko) 2001-03-28 2006-03-29 화이자 인코포레이티드 Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
BRPI0411985A (pt) * 2003-07-16 2006-08-29 Pfizer tratamento da disfunção sexual
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
EP1740181A1 (en) 2004-04-22 2007-01-10 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
RS52945B (sr) * 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
CA2604431A1 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) * 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
MY165575A (en) 2007-11-28 2018-04-05 Ucb Pharma Gmbh Polymorphic form of rotigotine

Also Published As

Publication number Publication date
PH12014501440A1 (en) 2016-02-01
BRPI0717856A2 (pt) 2013-10-29
EP2086545A2 (en) 2009-08-12
US20170157142A1 (en) 2017-06-08
AU2007314736A1 (en) 2008-05-08
HK1135038A1 (en) 2010-05-28
JP2014001235A (ja) 2014-01-09
UA100119C2 (uk) 2012-11-26
BRPI0718396A2 (pt) 2013-11-26
KR20160124246A (ko) 2016-10-26
JP2014055142A (ja) 2014-03-27
CN101557812A (zh) 2009-10-14
ZA200903835B (en) 2010-10-27
UA101948C2 (uk) 2013-05-27
JP2010509213A (ja) 2010-03-25
KR101796887B1 (ko) 2017-11-10
RU2463054C2 (ru) 2012-10-10
KR20090111802A (ko) 2009-10-27
RU2646447C2 (ru) 2018-03-05
CA2668317C (en) 2016-02-09
AU2007314734B2 (en) 2014-01-30
JP2015157849A (ja) 2015-09-03
UA103592C2 (uk) 2013-11-11
DK2086544T3 (en) 2016-02-08
CN101573119A (zh) 2009-11-04
IL198459A (en) 2016-11-30
CA2668320A1 (en) 2008-05-08
UA115647C2 (uk) 2017-12-11
JP2010509211A (ja) 2010-03-25
CY1117191T1 (el) 2017-04-05
IL237786A0 (en) 2015-05-31
NZ577390A (en) 2012-12-21
NZ577393A (en) 2012-11-30
US20120277200A1 (en) 2012-11-01
MX2009004696A (es) 2009-06-05
EP2086544B1 (en) 2015-12-23
ME02410B (me) 2016-09-20
WO2008054215A2 (en) 2008-05-08
BRPI0717963A2 (pt) 2013-11-05
KR20090115113A (ko) 2009-11-04
RS54541B1 (sr) 2016-06-30
ZA200903836B (en) 2010-08-25
MX2009004695A (es) 2009-06-05
EP1925307A1 (en) 2008-05-28
US20100093680A1 (en) 2010-04-15
CA2668320C (en) 2014-06-10
CN101563086A (zh) 2009-10-21
PH12014501821A1 (en) 2016-02-01
MX2009004693A (es) 2009-06-05
JP5748238B2 (ja) 2015-07-15
CN103381270A (zh) 2013-11-06
RU2491073C2 (ru) 2013-08-27
AU2007314734A1 (en) 2008-05-08
AU2007314735B2 (en) 2014-01-16
US8648060B2 (en) 2014-02-11
KR101578224B1 (ko) 2015-12-16
WO2008054213A3 (en) 2009-04-09
US8669242B2 (en) 2014-03-11
AU2007314735A1 (en) 2008-05-08
EP2086548A2 (en) 2009-08-12
US20160082018A1 (en) 2016-03-24
IL198461A0 (en) 2010-02-17
SI2086544T1 (sl) 2016-04-29
IL198459A0 (en) 2010-02-17
WO2008054214A2 (en) 2008-05-08
US20140121190A1 (en) 2014-05-01
RU2464027C2 (ru) 2012-10-20
KR20150038251A (ko) 2015-04-08
CN103599536A (zh) 2014-02-26
JP2014111608A (ja) 2014-06-19
WO2008054213A2 (en) 2008-05-08
RU2012125827A (ru) 2013-12-27
CA2668316C (en) 2014-06-10
NZ577392A (en) 2012-11-30
PT2086544E (pt) 2016-03-17
RU2009120992A (ru) 2010-12-10
NO343597B1 (no) 2019-04-08
PL2086544T3 (pl) 2016-07-29
US20140038929A1 (en) 2014-02-06
IL248563A0 (en) 2016-12-29
EP2086544A2 (en) 2009-08-12
NO20092143L (no) 2009-07-02
WO2008054214A3 (en) 2009-04-09
HRP20160108T1 (hr) 2016-03-25
US20140121189A1 (en) 2014-05-01
US9597335B2 (en) 2017-03-21
JP2010509212A (ja) 2010-03-25
IL198460A (en) 2016-11-30
IL248563B (en) 2018-11-29
WO2008054215A3 (en) 2009-04-09
ZA200903837B (en) 2010-08-25
HUE026752T2 (en) 2016-07-28
EP2937086A1 (en) 2015-10-28
US20100152145A1 (en) 2010-06-17
US8653051B2 (en) 2014-02-18
US20190262359A1 (en) 2019-08-29
CN104524580A (zh) 2015-04-22
PH12014501821B1 (en) 2016-02-01
NO20092146L (no) 2009-07-21
IL198460A0 (en) 2010-02-17
US10314848B2 (en) 2019-06-11
CA2668316A1 (en) 2008-05-08
US9211334B2 (en) 2015-12-15
CA2668317A1 (en) 2008-05-08
KR20090111803A (ko) 2009-10-27
RU2009120990A (ru) 2010-12-10
IL198461A (en) 2017-08-31
CN101563086B (zh) 2013-11-27
KR20150099620A (ko) 2015-08-31
ES2561946T3 (es) 2016-03-01
US20100160270A1 (en) 2010-06-24
RU2009120988A (ru) 2010-12-10
US8575139B2 (en) 2013-11-05
AU2007314736B2 (en) 2014-01-23
JP2017132809A (ja) 2017-08-03
JP6357131B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
NO20092145L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
WO2006114065A3 (en) Use of compounds to inhibit neoplasia
UA94221C2 (en) Lipocalin protein
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
MY160041A (en) Compositions and methods for treating parasitic infections
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
ZA200608024B (en) Use of flibanserin in the treatment of premenstrual and other female sexual disorders
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
EP1740183B8 (en) Novel use for pde5 inhibitors
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
HUE045846T2 (hu) Tesztoszteront és tadalafilt tartalmazó gyógyszerészeti kombinációk nõi nemi diszfunkciók kezelésére
MX343222B (es) Combinacion de teobrina con un descongestionante y su uso para el tratamiento de la tos.
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2005013946A3 (en) Methods of treatment inflammatory bowel with lxr agonists
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater
CA113510S (en) Wheel grip
WO2005023288A8 (en) Treatment of fibrotic disease
WO2005018620A3 (en) Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
AU311277S (en) Hammer
CA120869S (en) Artificial stone wall
CA120868S (en) Artificial stone wall

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EB IP LYBRIDO B.V., NL

FC2A Withdrawal, rejection or dismissal of laid open patent application